WebOct 4, 2024 · CDK12 and CDK13 were both ubiquitously expressed in primary and metastatic ovarian cancer, and the two kinases performed independent and synergistic … WebCDK12 inhibition may therefore form a general strategy for radiosensitization in oncology. CDK12 is co-amplified with HER2 (ERBB2) in ~20% of breast tumours; overexpression correlates with high proliferative index and grade 3 tumour status based on tissue microarrays. Conversely, some 13% of breast cancers and 5% of ovarian cancers …
Cancers Free Full-Text Novel CDK12/13 Inhibitors AU-15506 …
WebCDK12-IN-3 is a potent and selective CDK12 inhibitor with an IC50 of 491 nM in enzymatic assay. CDK12-IN-3 is a highly selective CDK12 inhibitor profiled across a panel of 352 kinases at 0.1 µM. CDK12-IN-3 shows potent inhibition of phosphorylation of Ser2 on the CTD repeat domain of RNA Pol II as well as growth inhibition of OV90 cells and ... WebApr 21, 2024 · The role of CDK12 in homologous recombination repair may also implicate this gene in PARP inhibitor sensitivity, as has been demonstrated in ovarian cancer. 10 Here, we aimed to characterize the clinical course and responsiveness to systemic therapies of a large cohort of patients with CDK12-altered prostate cancer, with particular … barkatullah khan stadium jodhpur
CDK12 inhibition reduces abnormalities in cells from patients …
WebApr 8, 2024 · CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced new preclinical data from our CDK12 inhibitor program, demonstrating robust anti-tumor activity of our oral, selective CDK12 inhibitors in models … WebJun 2, 2024 · For CDK12 and CDK13, energy transfer signals were more modest than the remaining family (Supplementary Fig. ... The CDK2 inhibitor K03861 49,50 engaged CDK8/19 in cells, ... WebMar 1, 2024 · Likewise, CDK12 knockdown or inhibition in CT26 cells delivered high sensitivity to lapatinib treatment, reconfirming that CDK12 is a potent modulator of lapatinib antitumour activity (Fig S2F and S2G). Therefore, we propose that HER2/CDK12 dual inhibition as a potential treatment strategy may warrant further clinical benefits for … suzuki dt65